Will Greece Indiges...
Health Care: Drugs
Mylan Inc (MYL: NASDAQ)
$22.89 0.36 | 1.60%
02/08/12 - 04:00 PM ET
4.69M / 5.62M
Vol / Avg. Vol:22.53 / 22.53
Open / Prev. Close:22.44 - 22.91
Today's Range:15.49 - 25.46
52 Wk Range:6.66%
Performance YTD:TheStreet Rating:
Portfolios with MYL
- Portfolio NameUser Type
- Contributor8 Pharma Stocks to Watch
- ContributorRocket Stocks for the Week ...
- ProJohn Paulson
- ProD.E. Shaw
- UserLA
- Contributor12 'Conviction Buys' on Gol...
- UserWatch List - Healthcare / B...
- Pro20 Most-Concentrated S&P 50...
- Contributor10 Most-Shorted S&P 500...
- ProFidelity Select Pharmaceuti...
Latest MYL Headlines from TheStreet
- UBS: 8 Pharma Stocks to Watch 01.20.12 | 12:01 pm
- 5 Stocks That Could Rocket Higher 12.27.11 | 09:12 am
- Hedge Fund Manager Dalio Piles Into Emerging Markets 11.15.11 | 05:11 am
- Mylan's CEO Discusses Q3 2011 Results - Earnings Call Transcript 10.26.11 | 02:10 pm
- 'Mad Money Lightning Round': SPDR Gold Shares ETF Shines 08.16.11 | 07:08 pm
- Mylan's CEO Discusses Q2 2011 Results - Earnings Call Transcript 07.27.11 | 05:07 pm
- Get Paid To Wait With Apache, AMR Converts
05.27.11 | 07:05 am - Bull-Market Skeptics Turn to 'Converts' 05.26.11 | 07:05 am
- RIM, Campbell Soup: Analysts' New Ratings 05.24.11 | 09:05 am
- Convertible Bonds, Stocks Under $10, Action Alerts Plus 05.23.11 | 05:05 pm
Press Releases for MYL
- Valeant Pharmaceuticals Completes Divestiture Of Generic Dermatology Products To Mylan - PR Newswire 02.06.12 | 08:02 am
- Mylan Completes Acquisition Of Two Limited-Competition Dermatological Products From Valeant - PR Newswire 02.06.12 | 08:02 am
- Mylan Receives Tentative FDA Approval For Generic Version Of Lipitor® - PR Newswire 02.02.12 | 07:02 am
- Mylan Confirms First-to-File Patent Challenge Relating To Actoplus Met® XR Tablets - PR Newswire 01.09.12 | 07:01 am
- Mylan Launches First Generic Version Of Teveten® Tablets - PR Newswire 12.27.11 | 03:12 pm
- Mylan Receives Approval For First-to-File Generic Keppra XR® Extended-Release Tablets - PR Newswire 12.27.11 | 07:12 am
- Mylan Receives WHO Approval For Innovative 'Second-Line-in-a-Box' HIV/AIDS Treatment - PR Newswire 12.20.11 | 07:12 am
- Mylan Launches Generic Version Of Toprol-XL® Tablets - PR Newswire 12.16.11 | 02:12 pm
- Mylan Names John Thievon President Of Dey Pharma - PR Newswire 12.12.11 | 07:12 am
- Mylan Launches Generic Version Of Cyklokapron® Injection - PR Newswire 12.02.11 | 07:12 am
Partner Headlines for MYL
- Zacks Bull and Bear of the Day Highlights: Mylan, JAKKS Pacific, Chevron, BP plc and ExxonMobil - Press Releases - Zacks 01.30.12 | 09:01 am
- Mylan, Inc. (MYL) - Bull of the Day - Zacks 01.30.12 | 01:01 am
- Zacks Bull and Bear of the Day Highlights: DaVita, Hhgregg, Mylan, Teva Pharmaceutical and Novartis - Press Releases - Zacks 01.25.12 | 09:01 am
- ETF Showdown: Fun With Pharma - Benzinga 12.30.11 | 04:12 pm
- The Zacks Analyst Blog Highlights: Teva Pharmaceuticals, Mylan, Watson Pharma, Dr. Reddy's and Novartis - Press Releases - Zacks 12.30.11 | 09:12 am
- Ring in Generics in 2012 and Beyond - Analyst Blog - Zacks 12.29.11 | 08:12 am
- Notable Put Options Activity in Mylan - Benzinga 12.21.11 | 01:12 pm
- 2012 Materials And Pharma Stock Picks From J.P. Morgan - Seeking Alpha 12.16.11 | 04:12 pm
- Billionaire David Shaw's Favorite Stock Picks - Seeking Alpha 12.15.11 | 09:12 am
- Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS - Benzinga 12.01.11 | 01:12 pm
